Liberty Health Sciences Secures GMP Certification At A Second Florida Cultivation, Manufacturing, and Processing Facility

• GMP certification covers a 10,000 square foot facility allowing for state-of-the-art extraction and processing area

TORONTO, Feb. 1, 2019 /CNW/ - Liberty Health Sciences Inc. (CSE: LHS) (OTCQX: LHSIF) www.libertyhealthsciences.com ("Liberty" or the "Company"), a provider of high quality cannabis, announced today that The British Standards Institution (BSI) has awarded a Good Manufacturing Practice (GMP) certificate to Liberty Health Sciences medical cannabis manufacturing facility, located at Liberty 360 Innovation Campus property in Gainesville, FL. Certification for this facility indicates that it also meets all of the Florida Department of Health (DOH) requirements pertaining to the processing, extraction and production of medical cannabis.

"Receiving GMP certification at an additional facility is a major milestone for Liberty Health Sciences and it demonstrates our commitment to producing the highest quality and safest products possible for  our customers throughout the state of Florida," said George Scorsis, CEO of Liberty Health Sciences. "This achievement reflects the incredibly high standards we expect of ourselves and that our clients expect as a patient provider. We will continue to produce the highest quality products and exceed production standards that surpass even the most stringent regulatory requirements."    

Jessica Engle, Director of Regulatory Compliance for Liberty Health Sciences said, "In addition to GMP compliance, Liberty has gone above and beyond the DOH requirements to create a fully operational HACCP (Hazard Analysis Critical Control Point) plan that helps ensure the products we produce are safe for consumers. The basis for HACCP is a scientific approach to preventative risk analysis. Every time a process changes, equipment changes, or raw material changes, our HACCP team meets to identify potential physical, chemical, and microbiological risks. Preventative measures are then put into place to help reduce the likelihood of the contamination hazard from ever occurring."

The GMP certification currently covers processing capabilities for 10,000 square feet at the Liberty 360 Innovation Campus. Currently, Liberty operates 20,000 square feet of cultivation space at the Liberty 360 Innovation Campus, as well as 40,000 square feet at the original Alachua property to support the growing demand for its product. Liberty expects to add an additional 160,000 square feet of cultivation space at the Liberty 360 Innovation Campus in Gainesville in 2019.  

About Liberty Health Sciences Inc.
Liberty is the cannabis provider committed to providing a trusted, high quality cannabis experience based on our genuine care for all cannabis users and a focus on operational excellence from seed to sale. Liberty's measured approach to expansion opportunities is focused on maximizing returns to shareholders, while keeping consumers' well-being at the forefront of what we do. For more information, please visit: www.libertyhealthsciences.com.       

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: This press release contains certain forward-looking statements within the meaning of applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as "may", "should", "anticipate", "expect", "believe", "plan", "intend" or the negative of these terms and similar expressions. Forward-looking statements in this news release include, but are not limited to, expectations related to the Company's production capabilities, expectations concerning the receipt of all necessary approvals from the Florida Department of Health, expectations concerning the opening of new dispensaries and the expansion of its greenhouse space, and the Company's future expansion and growth strategies. Forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; future legislative and regulatory developments involving medical marijuana; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favorable terms; the medical marijuana industry in the United States generally, income tax and regulatory matters; the ability of Liberty to implement its business strategies; competition; crop failure; currency and interest rate fluctuations and other risks. Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

SOURCE Liberty Health Sciences Inc.

Media Contacts: Dwain Schenck, 203-223-5230, [email protected]; Stephanie Kubacki, Vice-President, Marketing, 415-830-7337, [email protected]